Table 4 Interaction tests for OS, LFS and RR.
| Â | Risk factors | P-value | HR (95% CI) |
|---|---|---|---|
OS | Donor type | 0.981 | 0.975 (0.13–7.33) |
|  | Maintenance after transplantation | 0.056 | 0.247 (0.06–1.04) |
|  | MRD after 3 cycles of chemotherapy | 0.035 | 5.346(1.13–25.42) |
|  | TBI | 0.017 | 5.346(1.13–25.42) |
|  | MRD after 3 cycles of chemotherapy*TBI | 0.004 | 0.076(0.013–0.445) |
LFS | Maintenance after transplantation | 0.021 | 0.492 (0.27–0.90) |
|  | MRD after 3 cycles of chemotherapy | 0.018 | 2.836 (1.19–6.75) |
|  | TBI | 0.113 | 1.925(0.86–4.33) |
|  | MRD after 3 cycles of chemotherapy*TBI | 0.006 | 0.216(0.07–0.64) |
CIR | MRD after 3 cycles of chemotherapy | 0.019 | 2.960 (1.19–7.35) |
|  | Tbi | 0.950 | 1.030(0.41–2.60) |
|  | MRD after 3 cycles of chemotherapy*TBI | 0.075 | 0.320(0.09–1.12) |
NRM | Maintenance after transplantation | 0.020 | 0.09(0.01–0.69) |
|  | Tbi | 0.070 | 6.923(0.85–56.30) |
|  | MRD after 3 cycles of chemotherapy | 0.600 | 1.922(0.17–21.52) |
|  | MRD after 3 cycles of chemotherapy*TBI | 0.220 | 0.197(0.01–2.72) |
